A Phase 4 interventional study of Everolimus in Renal Angiomyolipoma, sponsored by Novartis Pharmaceuticals. Completed at 5 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2021-09-09.
Sponsored by Novartis Pharmaceuticals (part of Novartis) · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 17 studies testing everolimus in Tuberous Sclerosis — none open to participants now, 1 under way, 1 of them phase 3. Everolimus · Tuberous Sclerosis.
Among the 17 studies testing everolimus in Tuberous Sclerosis, this one is the 8th largest by enrollment, is the only one that started in 2018, is one of 2 in phase 4, and was the 16th registered.
115 studies on the registry are indexed under Tuberous Sclerosis; 27 are open to participants now.
Browse Tuberous Sclerosis studies →None of the 17 studies testing everolimus in Tuberous Sclerosis is open now. The open studies under Tuberous Sclerosis, anywhere →
Everolimus: first FDA approval 2009 (AFINITOR), first EMA approval 2009. What it is approved for, and how studies give it, is on its page →
Of the 21 Tuberous Sclerosis studies recruiting now, 10 (48%) set no upper age limit and 8 (38%) stop at 75 or younger; 15 take children under 18; 2 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
17 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 4 · Phase 2 11 · Phase 3 6 · Phase 4 2
First in 2005; this study’s year is marked. 1 started in 2018.
This study's enrollment of 40 is below the median of 52 across 73 interventional studies indexed under Tuberous Sclerosis.
Median enrollment 36 across the 17 interventional studies. Of the 13 that completed or were terminated, 10 (77%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 17 have an industry lead sponsor. The 9 most frequent:
This study is registered under Novartis Pharmaceuticals, one of the names counted as Novartis. Under that name alone:
Novartis Pharmaceuticals is the lead sponsor of 2,719 studies on the registry; 222 are open to participants now.
Of its 585 completed or terminated interventional studies of FDA-regulated products, 439 (75%) have results posted.
Novartis has 7 studies filed under Tuberous Sclerosis — fewer than ten, so there is no comparison to draw.
1 of the studies testing everolimus in Tuberous Sclerosis that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT02962414Phase 3Novartis PharmaceuticalsRoll-over Study to Collect and Assess Long-term Safety of Everolimus in Patients With TSC and Refractory Seizures Who Have Completed the EXIST-3 Study [CRAD001M2304] and Who Are Benefitting From Continued Treatment | 2027-02-26 |
Add it to your calendar (.ics) → With an account.
Among the 17 studies testing everolimus in Tuberous Sclerosis, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study was to assess the safety and efficacy of everolimus (Afinitor®) in Chinese patients with renal angiomyolipoma (AML) associated with tuberous sclerosis complex (TSC).
This was an open label, single arm, multi-center, Phase IV Post-Approval Commitment (PAC) study with once daily oral dose of 10 mg everolimus in participants with renal AML associated with TSC. There were three separate phases in this study: a Screening phase, an Open-label treatment phase where participants received everolimus for 48 weeks or until disease progression, and a Treatment discontinuation follow-up phase for patients who discontinue study drug for reasons other than disease progression. Every participant had an End of Treatment visit within 28 days after last dose and a safety follow-up visit 30 days after last dose.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants targeted to receive Everolimus tablets 10 mg orally once daily for 48 weeks.
Drug: Everolimus
Everolimus 2.5 mg and 5 mg tablets with dosage regimen of 10 mg orally once daily.
Also known as: RAD001, Afinitor®
Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs)
Percentage of participants with AEs and SAEs including significant changes from baseline in vital signs, electrocardiograms and laboratory parameters (laboratory assessments included hematology, biochemistry, coagulation and urinalysis) qualifying and reported as AEs. The percentage of participants in each category is reported in the table.
Time frame: From the start of treatment to 30 days after end of treatment, assessed up to maximum duration of 52 weeks
Percentage of Participants With Best Overall Response (BOR) Status of Angiomyolipoma (AML) Response During Maximum Treatment Duration of 48 Weeks
BOR status is the best status recorded from start of treatment until disease progression. AML response status: reduction in AML volume of at least 50% relative to screening AML. In addition, AML response have to satisfy: no new AML ≥ 1 cm in longest diameter are identified, neither kidney increases in volume by more than 20% from nadir (where nadir is the lowest kidney volume at the screening), the participant does not have any angiomyolipoma-related bleeding of grade equal or over 2 (as defined by NCI CTCAE, version 4.03). Up to five of the largest measurable lesions (≥ 1 cm in longest diameter) in each kidney were measured at screening via Magnetic Resonance Imaging/Computed tomography (MRI/CT) and were defined as screening AML. The sum of the volumes of these individual lesions was defined as AML volume and it was measured at each assessment during the trial. Increases in the AML volume were evidence of worsening AML, decreases were evidence of clinical response.
Time frame: Baseline, 48 weeks
Percentage of Participants With Best Overall Response Status of Angiomyolipoma (AML) Progression During Maximum Treatment Duration of 48 Weeks
AML progression status is defined as one or more of the following: an increase from nadir of 25% or more in AML volume to a value greater than screening AML (where nadir is the lowest AML volume obtained for the participant previously in the trial), the appearance of a new AML ≥ 1.0 cm in longest diameter, an increase from nadir of 20% or more in the volume of either kidney to a value greater than screening (where nadir is the lowest kidney volume obtained for the participant previously in the trial), angiomyolipoma-related bleeding grade ≥2 (as defined by NCI CTCAE, version 4.03). Up to five of the largest measurable lesions (≥ 1 cm in longest diameter) in each kidney were measured at screening via Magnetic Resonance Imaging/Computed tomography (MRI/CT) and were defined as screening AML. The sum of the volumes of these individual lesions was defined as AML volume and it was measured at each assessment during the trial. Increases in the AML volume were evidence of worsening AML.
Time frame: Baseline, 48 weeks
Percentage of Participants With Severe Renal Impairment
Renal impairment is defined as calculated Creatinine Clearance (CrCl) \< 30 mL/min. CrCl was measured at baseline and at four other time points; only the baseline and the worst post-baseline value for every participant were counted (lowest value for CrCl). Creatinine clearance was estimated using the Cockcroft-Gault formula: creatinine clearance (mL/minute) = urine creatinine concentration (mL/dL) x volume of urine (mL/24 hour) / plasma creatinine concentration (mg/dL) x 1440 minute/24 hour
Time frame: Baseline, 48 weeks
Percentage of Participants With NCI CTCA Grade 3/4 Serum Creatinine
NCI CTCAE grade 3/4 serum creatinine is defined as \> 3.0 x upper limits of normal (ULN). Serum creatinine was measured at baseline and at four other time points; only the worst post-baseline value for every participant was counted (highest value for serum creatinine).
Time frame: Baseline, 48 weeks
All participants were enrolled in 5 different sites in China.
| Milestone | Everolimus |
|---|---|
| Started | 40 |
| Completed | 39 |
| Not completed | 1 |
| Withdrew: Progressive disease | 1 |
Percentage of participants with AEs and SAEs including significant changes from baseline in vital signs, electrocardiograms and laboratory parameters (laboratory assessments included hematology, biochemistry, coagulation and urinalysis) qualifying and reported as AEs. The percentage of participants in each category is reported in the table.
| Participants | Everolimus |
|---|---|
| AEs | 40 |
| Treatment-related AEs | 39 |
| SAEs | 6 |
| Treatment-related SAEs | 2 |
BOR status is the best status recorded from start of treatment until disease progression. AML response status: reduction in AML volume of at least 50% relative to screening AML. In addition, AML response have to satisfy: no new AML ≥ 1 cm in longest diameter are identified, neither kidney increases in volume by more than 20% from nadir (where nadir is the lowest kidney volume at the screening), the participant does not have any angiomyolipoma-related bleeding of grade equal or over 2 (as defined by NCI CTCAE, version 4.03). Up to five of the largest measurable lesions (≥ 1 cm in longest diameter) in each kidney were measured at screening via Magnetic Resonance Imaging/Computed tomography (MRI/CT) and were defined as screening AML. The sum of the volumes of these individual lesions was defined as AML volume and it was measured at each assessment during the trial. Increases in the AML volume were evidence of worsening AML, decreases were evidence of clinical response.
| Participants | Everolimus |
|---|---|
| Percentage of Participants With Best Overall Response (BOR) Status of Angiomyolipoma (AML) Response During Maximum Treatment Duration of 48 Weeks | 28 |
AML progression status is defined as one or more of the following: an increase from nadir of 25% or more in AML volume to a value greater than screening AML (where nadir is the lowest AML volume obtained for the participant previously in the trial), the appearance of a new AML ≥ 1.0 cm in longest diameter, an increase from nadir of 20% or more in the volume of either kidney to a value greater than screening (where nadir is the lowest kidney volume obtained for the participant previously in the trial), angiomyolipoma-related bleeding grade ≥2 (as defined by NCI CTCAE, version 4.03). Up to five of the largest measurable lesions (≥ 1 cm in longest diameter) in each kidney were measured at screening via Magnetic Resonance Imaging/Computed tomography (MRI/CT) and were defined as screening AML. The sum of the volumes of these individual lesions was defined as AML volume and it was measured at each assessment during the trial. Increases in the AML volume were evidence of worsening AML.
| Participants | Everolimus |
|---|---|
| Percentage of Participants With Best Overall Response Status of Angiomyolipoma (AML) Progression During Maximum Treatment Duration of 48 Weeks | 1 |
Renal impairment is defined as calculated Creatinine Clearance (CrCl) \< 30 mL/min. CrCl was measured at baseline and at four other time points; only the baseline and the worst post-baseline value for every participant were counted (lowest value for CrCl). Creatinine clearance was estimated using the Cockcroft-Gault formula: creatinine clearance (mL/minute) = urine creatinine concentration (mL/dL) x volume of urine (mL/24 hour) / plasma creatinine concentration (mg/dL) x 1440 minute/24 hour
| Participants | Everolimus |
|---|---|
| Baseline | 0 |
| Post-baseline, 48 weeks | 1 |
NCI CTCAE grade 3/4 serum creatinine is defined as \> 3.0 x upper limits of normal (ULN). Serum creatinine was measured at baseline and at four other time points; only the worst post-baseline value for every participant was counted (highest value for serum creatinine).
| Participants | Everolimus |
|---|---|
| Baseline | 0 |
| Post-baseline, 48 weeks | 0 |
Collected over Adverse events were reported from first dose of study treatment until end of study treatment plus 30 days post treatment, up to a maximum duration of 52 weeks.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Everolimus | 0/40 (0%) | 6/40 (15%) | 39/40 (97.5%) |
| Event | Everolimus |
|---|---|
| HaemorrhoidsGastrointestinal disorders | 1/40 |
| StomatitisGastrointestinal disorders | 1/40 |
| GastroenteritisInfections and infestations | 1/40 |
| PneumoniaInfections and infestations | 1/40 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/40 |
| Transient psychosisPsychiatric disorders | 1/40 |
| Event | Everolimus |
|---|---|
| StomatitisGastrointestinal disorders | 18/40 |
| Mouth ulcerationGastrointestinal disorders | 15/40 |
| Blood triglycerides increasedInvestigations | 11/40 |
| Blood cholesterol increasedInvestigations | 10/40 |
| HypercholesterolaemiaMetabolism and nutrition disorders | 10/40 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 10/40 |
| AnaemiaBlood and lymphatic system disorders | 8/40 |
| Blood lactate dehydrogenase increasedInvestigations | 8/40 |
| Protein urine presentInvestigations | 8/40 |
| Alanine aminotransferase increasedInvestigations | 7/40 |
| Age, Continuous(Years) | Everolimus |
|---|---|
| Mean | 33.7 ± 10.80 |
| Sex: Female, Male(Participants) | Everolimus |
|---|---|
| Female | 26 |
| Male | 14 |
| Race/Ethnicity, Customized(Participants) | Everolimus |
|---|---|
| Race — Asian, Chinese | 40 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent review panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations. This trial data availability is according to the criteria and process described on https://www.clinicalstudydatarequest.com/.
Ran from Nov 2018 to primary completion in Sep 2020, 22 months.
Results were first posted in Sep 2021, 11 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Sep 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Everolimus